Compare MCRB & AXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCRB | AXR |
|---|---|---|
| Founded | 2010 | 1961 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.7M | 144.1M |
| IPO Year | 2015 | 2010 |
| Metric | MCRB | AXR |
|---|---|---|
| Price | $8.84 | $27.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $14.00 | ★ $30.00 |
| AVG Volume (30 Days) | ★ 39.3K | 10.9K |
| Earning Date | 05-06-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.60 |
| EPS | 0.64 | ★ 1.68 |
| Revenue | $789,000.00 | ★ $12,831,000.00 |
| Revenue This Year | N/A | $12.43 |
| Revenue Next Year | N/A | $4.48 |
| P/E Ratio | ★ $13.45 | $16.79 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.36 | $17.61 |
| 52 Week High | $29.98 | $29.00 |
| Indicator | MCRB | AXR |
|---|---|---|
| Relative Strength Index (RSI) | 46.20 | 53.34 |
| Support Level | $7.98 | $19.45 |
| Resistance Level | $9.53 | $28.52 |
| Average True Range (ATR) | 0.59 | 1.62 |
| MACD | 0.06 | -0.11 |
| Stochastic Oscillator | 40.59 | 70.91 |
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve obtaining approvals and selling both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. The Company accounts for land sales, home sales, and other revenues. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.